Emerald Advisers Inc. PA Sells 11,973 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Emerald Advisers Inc. PA lowered its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 82.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,520 shares of the medical instruments supplier’s stock after selling 11,973 shares during the period. Emerald Advisers Inc. PA’s holdings in West Pharmaceutical Services were worth $238,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of WST. Burt Wealth Advisors increased its position in shares of West Pharmaceutical Services by 38,540.0% in the first quarter. Burt Wealth Advisors now owns 1,932 shares of the medical instruments supplier’s stock worth $158,000 after buying an additional 1,927 shares in the last quarter. Harfst & Associates Inc. acquired a new position in shares of West Pharmaceutical Services during the first quarter worth about $186,000. CIBC Asset Management Inc acquired a new position in shares of West Pharmaceutical Services during the second quarter worth about $223,000. Tyers Asset Management LLC increased its position in shares of West Pharmaceutical Services by 17.6% in the first quarter. Tyers Asset Management LLC now owns 2,464 shares of the medical instruments supplier’s stock worth $201,000 after buying an additional 368 shares in the last quarter. Finally, Cutler Group LP increased its position in shares of West Pharmaceutical Services by 482.2% in the second quarter. Cutler Group LP now owns 2,550 shares of the medical instruments supplier’s stock worth $241,000 after buying an additional 2,112 shares in the last quarter. 90.51% of the stock is currently owned by hedge funds and other institutional investors.

Shares of West Pharmaceutical Services, Inc. (NYSE:WST) traded down 0.19% during trading on Friday, reaching $85.15. The company’s stock had a trading volume of 249,608 shares. The company has a 50 day moving average price of $90.44 and a 200 day moving average price of $88.85. West Pharmaceutical Services, Inc. has a 52 week low of $70.17 and a 52 week high of $99.91. The firm has a market capitalization of $6.30 billion, a P/E ratio of 36.55 and a beta of 1.10.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. The business had revenue of $397.60 million for the quarter, compared to analyst estimates of $406 million. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The company’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.59 EPS. On average, equities research analysts expect that West Pharmaceutical Services, Inc. will post $2.69 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Wednesday, October 18th will be paid a dividend of $0.14 per share. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.13. The ex-dividend date is Tuesday, October 17th. This represents a $0.56 annualized dividend and a dividend yield of 0.66%. West Pharmaceutical Services’s payout ratio is 22.22%.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.com-unik.info/2017/08/19/west-pharmaceutical-services-inc-nysewst-shares-sold-by-emerald-advisers-inc-pa-updated-updated.html.

A number of equities analysts have issued reports on the company. Zacks Investment Research upgraded West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating and set a $114.00 price target on the stock in a research report on Friday, June 9th. BidaskClub downgraded West Pharmaceutical Services from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $90.18.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

What are top analysts saying about West Pharmaceutical Services Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for West Pharmaceutical Services Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit